Solid Biosciences (SLDB) Total Non-Current Liabilities (2018 - 2026)

Solid Biosciences (SLDB) has 7 years of Total Non-Current Liabilities data on file, last reported at $18.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 10.57% year-over-year to $18.5 million; the trailing twelve-month figure through Mar 2026 stood at $18.5 million (down 10.57% YoY), and the FY2025 full-year result was $19.1 million, down 9.93% from the prior year.
• Total Non-Current Liabilities eased to $18.5 million in Q1 2026, from $19.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $48.5 million in Q4 2022 to a low of $18.5 million in Q1 2026.
• A 5-year average of $23.7 million and a median of $20.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 50.63% in 2023 and decreased 9.93% in 2025, its largest moves.
• Tracing SLDB's Total Non-Current Liabilities over 5 years: stood at $48.5 million in 2022, then plunged by 50.63% to $23.9 million in 2023, then decreased by 11.62% to $21.2 million in 2024, then dropped by 9.93% to $19.1 million in 2025, then slipped by 3.04% to $18.5 million in 2026.
• Business Quant data shows SLDB's Total Non-Current Liabilities at $18.5 million in Q1 2026, $19.1 million in Q4 2025, and $19.6 million in Q3 2025.